GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy Men
- Conditions
- AtherosclerosisCardiovascular Disease
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 44
- Registration Number
- NCT00549653
- Locations
- 🇺🇸
GSK Investigational Site, Dallas, Texas, United States
A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2018-07-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00549900
- Locations
- 🇨🇳
GSK Investigational Site, Jintan City, Jiangsu, China
Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 104
- Registration Number
- NCT00549679
- Locations
- 🇸🇰
GSK Investigational Site, Martin, Slovakia
Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing
- Conditions
- Asthma
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 78
- Registration Number
- NCT00549744
- Locations
- 🇿🇦
GSK Investigational Site, Bloemfontein, South Africa
Optimising the Propranolol Block Model
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2007-10-25
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00549120
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2007-10-25
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 14
- Registration Number
- NCT00549328
- Locations
- 🇺🇸
GSK Investigational Site, Seattle, Washington, United States
A Randomized Study Evaluating Steroid Hormone Levels, Safety And Tolerability Of GW870086X In Healthy Volunteers
- First Posted Date
- 2007-10-25
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT00549497
- Locations
- 🇦🇺
GSK Investigational Site, Herston, Queensland, Australia
Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2007-10-25
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 290
- Registration Number
- NCT00549146
- Locations
- 🇳🇱
GSK Investigational Site, Voerendaal, Netherlands
A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.
- Conditions
- Obstetric Labour, PrematurePremature Ejaculation
- First Posted Date
- 2007-10-25
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 42
- Registration Number
- NCT00549211
- Locations
- 🇺🇸
GSK Investigational Site, Evansville, Indiana, United States
Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.
- Conditions
- Hypertension
- First Posted Date
- 2007-10-25
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 29
- Registration Number
- NCT00549510
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States